425: Apimeds Merges with MindWave, Securing $120.9M PIPE for Biotech & Digital Asset Growth

Apimeds Pharmaceuticals US, Inc. has completed a merger with MindWave Innovations Inc., combining its biopharmaceutical pipeline with MindWave's AI-driven Bitcoin treasury and digital asset yield generation, supported by a private investment of up to $120.9 million.

Summary

• Apimeds Pharmaceuticals US, Inc. (Acquiror) has merged with MindWave Innovations Inc. (Company), with MindWave becoming a direct wholly-owned subsidiary of Apimeds.
• MindWave stockholders received 29.9% of the total outstanding Acquiror Common Stock and 61% of the total issued and outstanding equity securities of the Acquiror on an as-converted, fully diluted basis, collectively representing 90.9% of the equity capital.
• The merger is supported by a private placement offering (PIPE) of up to $120.9 million in senior convertible notes, issued at an 8% original issue discount.
• Initial funding from the PIPE is $10,875,000, with an additional $2,175,000 to be funded upon the effectiveness of a resale registration statement.
• The remaining $96,950,000 of the PIPE is subject to mutual consent for purchase by the investor.
• The convertible notes mature in 12 months and are convertible at 80% of the lowest daily volume-weighted average price (VWAP) during a 5-trading day period.
• Monthly conversions of the notes are limited to the greater of 20% of the aggregate daily traded value or $2.25 million.
• Apimeds' existing clinical-stage biopharmaceutical business, focused on Apitox, will be transferred to a wholly-owned subsidiary, Lokahi Therapeutics, Inc. (Bio Sub).
• Bio Sub is required to be preserved and operated consistent with past practices for six months or until $14,800,000 is raised for it, and cannot incur indebtedness exceeding $2,000,000 without the Acquiror CEO's consent.
• The Company (MindWave) owns 1,000 Bitcoin in its wholly-owned subsidiary, TechyTrade FZ LLC, held in segregated sub-wallet structures with private keys under TechyTrade FZ LLC's custody and ownership.
• A reverse stock split of 1-for-10 for Acquiror Common Stock and a change in par value from $0.01 to $0.001 are planned.
• The Acquiror's 2024 Equity Incentive Plan will be amended to increase shares by 2,096,679, and a new 2025 Equity Incentive Plan will be adopted.
• A warrant was issued to E.F. Hutton & Co. LLC to purchase 712,880 shares of Acquiror Common Stock at an exercise price of $1.8372 per share, exercisable from December 1, 2025, to December 1, 2030.

Sentiment

Score: 7

Explanation: The merger and significant PIPE financing are positive for growth and diversification, but the integration of two distinct industries and the inherent risks of both biotech and volatile digital asset markets warrant a balanced outlook.

Positives

• The merger creates a diversified enterprise combining high-growth biotechnology with institutional digital-asset financial technology, potentially leading to diversified revenue streams.
• The significant PIPE financing of up to $120.9 million provides substantial capital to accelerate Apimeds' therapeutic programs and expand MindWave's digital asset infrastructure.
• MindWave's AI-driven Bitcoin treasury and yield-generation capabilities are positioned in a fast-growing segment of the digital-asset market, offering strong cash-flow potential.
• The NYSE American listing provides a public platform for MindWave's institutional-focused Digital Asset Treasury (DAT) model.
• The appointment of Dr. Vin Menon, MindWave's founder and CEO, as the new CEO of the combined entity brings leadership experienced in disruptive technology and high-growth companies.
• The retention of Erik Emerson as President of the Acquiror and CEO/President of Bio Sub ensures continuity for the biopharmaceutical business.

Negatives

• The merger involves integrating two disparate businesses (biopharmaceutical and digital asset fintech), which can present significant operational and cultural challenges.
• The substantial equity dilution for existing Acquiror stockholders, with MindWave holders collectively receiving 90.9% of the combined entity's equity, could be a concern.
• The convertible notes are issued at an 8% original issue discount, which is a cost to the company.
• The monthly conversion limits for the notes (greater of 20% of daily traded value or $2.25 million) could impact the speed at which the investor can convert and sell shares, potentially creating selling pressure over time.
• The requirement for Bio Sub to operate consistent with past practices and its indebtedness limit of $2,000,000 without CEO consent could restrict its flexibility during the Post-Closing Period.

Risks

• Unsuccessful integration of Apimeds' and MindWave's businesses.
• Synergies and growth from the merger may not be fully realized or may take longer than expected.
• Potential adverse reactions or changes to business or employee relationships resulting from the announcement or completion of the merger.
• Failure to obtain or maintain required NYSE American listing approvals or satisfy continued listing standards.
• Inability to consummate planned financings on acceptable terms or within expected timeframes.
• Volatility in bitcoin markets impacting collateral requirements for digital assets.
• Changes in the Acquiror's capital structure and governance following the merger could have adverse effects on the market value of its securities.
• Inability to retain customers and key personnel, and maintain relationships with suppliers and customers.
• The merger could distract management from ongoing business operations or cause the combined company to incur substantial costs.
• Inability to reduce expenses or access financing or liquidity.
• Impact of any related economic downturn.
• Changes in governmental regulations or enforcement practices, particularly in the evolving digital asset space.

Future Outlook

The combined company aims to drive long-term value and maximize stockholder returns by integrating high-growth biotechnology with institutional digital-asset financial technology. This strategy is expected to accelerate therapeutic programs and expand digital asset infrastructure, leveraging MindWave's AI-driven Bitcoin treasury and yield-generation capabilities. The company anticipates moving Apitox towards Phase 3 clinical trials and building a publicly traded, institutional-focused Digital Asset Treasury (DAT) model.

Management Comments

• Erik Emerson, CEO of Apimeds, stated: 'As Apimeds moves toward its Phase 3 clinical trial initiation, we continue to focus on financing and expansion. When I met the leadership team at MindWave and saw the strength and scalability of their business, it became clear this merger represented a unique opportunity. Biotech requires significant capital, and integrating a high-yield digital asset business with strong cash-flow potential will allow us to accelerate our therapeutic programs.'
• Dr. Vin Menon, Founder and CEO of MindWave, noted: 'The NYSE American listing, combined with our three-pronged approach to Bitcoin Treasury infrastructure, refined AI-supported yield capabilities, and a scalable multi-vertical ecosystem powered by the $NILA token, positions MindWave at the forefront of institutional digital treasury management. Joining forces with Apimeds creates a diversified organization designed to drive long-term value and maximize stockholder returns.'

Industry Context

This merger represents a notable convergence of two distinct, high-growth sectors: clinical-stage biopharmaceuticals and digital asset financial technology. Apimeds' focus on non-opioid pain management addresses a critical need in healthcare, while MindWave's AI-driven Bitcoin treasury and yield generation taps into the rapidly expanding institutional interest in digital assets. The combined entity aims to leverage the capital-intensive nature of biotech with the cash-flow potential of digital asset management, positioning itself as a diversified player in both innovation and financial technology. This move could set a precedent for how companies in traditional sectors seek to fund growth and manage capital through integration with the digital economy.

Comparison to Industry Standards

• The D&O liability insurance for post-Closing directors and officers will be maintained on terms consistent with market standards for companies of similar size and listing status, with an extended coverage for pre-Closing directors and officers for six years after the Effective Time, subject to a premium cap of 350% of current annual premiums.
• The company aims to be 'one of the first companies to pursue a publicly traded, institutional-focused Digital Asset Treasury (DAT) model,' suggesting a novel approach compared to existing industry structures.

Management Changes

Corporate Governance

Related Party Transactions

• Erik Emerson, in his capacity as representative for the Bio Business, is a party to the Merger Agreement.
• Erik Emerson is also a Stockholder of the Acquiror, holding 750,000 Subject Shares.
• Inscobee Inc. and Apimeds Inc. are also Stockholders of the Acquiror, holding 2,099,747 and 4,316,618 Subject Shares respectively, and are parties to the Stockholder Support Agreement.
• The Bio Sub Loan of $2,500,000 from Bio Sub to TechyTrade is a related party transaction, to be repaid from future financing proceeds.

Stakeholder Impact

• Shareholders of Apimeds will experience significant dilution, with former MindWave stockholders holding 90.9% of the combined entity's equity, potentially impacting their ownership percentage and voting power.
• Shareholders of MindWave will gain public market access and liquidity through the NYSE American listing.
• Employees of both companies may experience changes in management and corporate structure, with potential for new incentive plans and strategic direction.
• Customers and suppliers of both Apimeds and MindWave may see changes in business relationships and operational focus as the companies integrate.
• Creditors of Apimeds will see a new capital structure with up to $120.9 million in new senior convertible debt, which could impact the company's leverage and credit profile.
• The biopharmaceutical segment (Bio Business) will continue its operations under a new subsidiary (Bio Sub) with dedicated funding targets, potentially benefiting its development programs.

Next Steps

• Acquiror to prepare and file a written information statement (Schedule 14C) with the SEC concerning the Written Consent, Proposals, and Merger.
• Acquiror to disseminate the definitive Information Statement to its stockholders, followed by a 20-calendar day waiting period for proposals to become effective.
• Acquiror to cause the Charter Amendment to be filed with the DE SOS to implement the 1-for-10 Reverse Stock Split.
• Acquiror to cause the Series A Preferred Stock to be converted into Acquiror Common Stock after the Reverse Stock Split is effective and NYSE American approval is obtained.
• Acquiror to file a resale registration statement on Form S-1 within 45 days of closing and aim for effectiveness within 75 days (or 120 days with full SEC review).
• Acquiror to file a registration statement on Form S-8 within five business days following the Action Effective Time to register additional shares under the 2024 Equity Incentive Plan.
• Company to deliver unaudited interim financial statements within 75 days after the Closing Date.
• Acquiror to file financial statements of the acquired business and pro forma financial information as an amendment to the 8-K no later than 71 calendar days after the required filing for this 8-K.

Key Dates

Recommendation

The merger is a transformative event, combining a clinical-stage biopharmaceutical company with a digital asset fintech firm, backed by substantial PIPE financing. This diversification could offer new growth avenues and funding mechanisms. However, the significant equity shift to MindWave holders, the complexities of integrating two disparate businesses, and the inherent volatility of the digital asset market introduce considerable risks. While the capital raise is a positive, the long-term success hinges on effective integration and execution in both sectors. A 'hold' recommendation is appropriate as investors should monitor the integration process, the realization of stated synergies, and the performance of both business segments before making further investment decisions.

Keywords

Biotechnology, Digital Assets, Merger, AI-driven Treasury, Convertible Notes, PIPE Financing, Apitox, Pain Management, Bitcoin Yield Generation, NYSE American, Corporate Governance, SEC Filing, Pharmaceuticals, Fintech